Zilganersen

Ionis Pharmaceuticals announced FDA Fast Track designation for zilganersen, an investigational treatment for Alexander disease, with topline data expected in H2 2025. Zilganersen targets the underlying cause of the disease by inhibiting excess GFAP production. The Phase 1-3 study completed enrollment across 13 sites in 8 countries.